NPR logo Many Insurers Don't Cover Drugs For Weight Loss

Your Health

Many Insurers Don't Cover Drugs For Weight Loss

Belviq, a weight-loss drug from Arena Pharmaceuticals, was approved by the Food and Drug Administration in 2012. With the agency's approval of Saxenda in December, there are four new weight-loss pills available. i

Belviq, a weight-loss drug from Arena Pharmaceuticals, was approved by the Food and Drug Administration in 2012. With the agency's approval of Saxenda in December, there are four new weight-loss pills available. Arena Pharmaceuticals Inc/Reuters/Landov hide caption

toggle caption Arena Pharmaceuticals Inc/Reuters/Landov
Belviq, a weight-loss drug from Arena Pharmaceuticals, was approved by the Food and Drug Administration in 2012. With the agency's approval of Saxenda in December, there are four new weight-loss pills available.

Belviq, a weight-loss drug from Arena Pharmaceuticals, was approved by the Food and Drug Administration in 2012. With the agency's approval of Saxenda in December, there are four new weight-loss pills available.

Arena Pharmaceuticals Inc/Reuters/Landov

In December, the Food and Drug Administration approved a new obesity drug, Saxenda, the fourth prescription medicine the agency has given the green light to fight obesity since 2012. But even though two-thirds of adults are overweight or obese, there's a good chance their insurer won't cover Saxenda or other anti-obesity drugs.

The health benefits of using obesity drugs to lose weight — improvements in blood sugar and risk factors for heart disease, among other things — may not be immediately apparent. "For things that are preventive in the long term, it makes plan sponsors think about their strategy," says Dr. Steve Miller, the chief medical officer at Express Scripts, which manages the prescription drug benefits for thousands of companies. Companies with high turnover, for example, are less likely to cover the drugs, he says.

"Most health plans will cover things that have an immediate impact in that plan year," Miller says.

Miller estimates that about a third of companies don't cover obesity drugs at all, a third cover all FDA-approved weight-loss drugs, and a third cover approved drugs, but with restrictions to limit their use. The Medicare prescription drug program specifically excludes coverage of obesity drugs.

Part of the reluctance by Medicare and private insurers to cover weight-loss drugs stems from serious safety problems with diet drugs in the past, including the withdrawal in 1997 of fenfluramine, part of the fen-phen diet drug combination that was found to damage heart valves.

Back then, weight-loss drugs were often dismissed as cosmetic treatments. But as the link between obesity and increased risk for Type 2 diabetes, heart disease, cancer and other serious medical problems has become clearer, prescription drugs are seen as having a role to play in addressing the obesity epidemic. Obesity accounts for 21 percent of annual medical costs in the United States, or $190 billion, according to a 2012 study published in the Journal of Health Economics.

The recently approved drugs— Belviq, Qsymia, Contrave and Saxenda—work by suppressing appetite, among other things. In conjunction with diet and exercise, people typically lose between 5 and 10 percent of their body weight, research shows, modest weight loss but sufficient to meaningfully improve health.

The drugs are generally recommended for people with a body mass index of 30 or higher, the threshold for obesity. They may also be appropriate for overweight people with BMIs in the high 20s if they have heart disease, diabetes or other conditions.

Many people who take an obesity drug may remain on it for the rest of their lives. That gives insurers pause, says Miller.

The potential cost to insurers could be enormous, he says.

Susan Pisano, a spokesperson for America's Health Insurance Plans, a trade group, says the variability of insurer coverage of obesity drugs "relates to issues of evidence of effectiveness and evidence of safety."

Dr. Caroline Apovian, director of the Nutrition and Weight Management Research Center at Boston University, says many of the patients she treats can't afford to pay up to $200 a month out of pocket for obesity drugs.

"Coverage has to happen in order for the obesity problem to be taken care of," says Apovian. "Insurance companies need to realize it's not a matter of willpower, it's a disease."

Comments

 

Please keep your community civil. All comments must follow the NPR.org Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.